Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.

De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.

Blood. 2020 Jan 30;135(5):381-386. doi: 10.1182/blood.2019002614.

PMID:
31869407
2.

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.

Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N.

Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20.

PMID:
31860137
3.

A Western Case of Intravascular Large B-Cell Lymphoma as Unusual Cause of Persistent Fever.

Piccaluga PP, Paolini S, Campidelli C, Vianelli N, Bolondi L.

Case Rep Hematol. 2019 Nov 16;2019:1480710. doi: 10.1155/2019/1480710. eCollection 2019.

4.

Second cancers in MPN: Survival analysis from an international study.

Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.

Am J Hematol. 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700. Epub 2019 Dec 22.

PMID:
31816122
5.

Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years.

Palandri F, Santoro C, Carpenedo M, Cantoni S, Barcellini W, Carli G, Carrai V, Rossi E, Rivolti E, Lucchesi A, Rotondo F, Baldacci E, Auteri G, Sutto E, Di Pietro C, Catani L, Bartoletti D, De Stefano V, Ruggeri M, Mazzucconi MG, Cavo M, Rodeghiero F, Vianelli N.

Thromb Res. 2020 Jan;185:88-95. doi: 10.1016/j.thromres.2019.11.026. Epub 2019 Nov 21.

PMID:
31783273
6.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.

Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.

Am J Hematol. 2020 Feb;95(2):156-166. doi: 10.1002/ajh.25677. Epub 2019 Nov 29.

PMID:
31721282
7.

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.

Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G.

Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29.

PMID:
31142846
8.

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.

Hematol Oncol. 2019 Oct;37(4):418-423. doi: 10.1002/hon.2619. Epub 2019 Jun 7.

PMID:
30985017
9.

Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies.

Stanzani M, Vianelli N, Cavo M, Kontoyiannis DP, Lewis RE.

J Infect. 2019 Jun;78(6):484-490. doi: 10.1016/j.jinf.2019.04.002. Epub 2019 Apr 8.

PMID:
30974130
10.

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.

Fattizzo B, Pasquale R, Carpenedo M, Cantoni S, Auteri G, Gramegna D, D'Adda M, Napolitano M, Consonni D, Ruggeri M, Siragusa S, Rossi G, Vianelli N, Barcellini W.

Haematologica. 2019 Oct;104(10):e470-e473. doi: 10.3324/haematol.2019.216804. Epub 2019 Mar 7. No abstract available.

11.

Fungaemia in haematological malignancies: SEIFEM-2015 survey.

Criscuolo M, Marchesi F, Candoni A, Cattaneo C, Nosari A, Veggia B, Verga L, Fracchiolla N, Vianelli N, Del Principe MI, Picardi M, Tumbarello M, Aversa F, Busca A, Pagano L; SEIFEM Group (Sorveglianza Epidemiologica Infezioni nelle Emopatie).

Eur J Clin Invest. 2019 May;49(5):e13083. doi: 10.1111/eci.13083. Epub 2019 Mar 7.

PMID:
30735240
12.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
13.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542
14.

Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis.

Barone M, Ricci F, Sollazzo D, Ottaviani E, Romano M, Auteri G, Bartoletti D, Reggiani MLB, Vianelli N, Tazzari PL, Cavo M, Forte D, Palandri F, Catani L.

Br J Haematol. 2019 Jun;185(5):987-991. doi: 10.1111/bjh.15682. Epub 2018 Nov 18. No abstract available.

PMID:
30450539
15.

Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients.

Palandri F, Catani L, Auteri G, Bartoletti D, Fatica S, Fusco A, Bacchi Reggiani ML, Cavo M, Vianelli N.

Br J Haematol. 2019 Feb;184(3):424-430. doi: 10.1111/bjh.15668. Epub 2018 Nov 8.

PMID:
30408157
16.

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G.

Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5. No abstract available.

PMID:
30321784
17.

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34+ Cells.

Forte D, Sollazzo D, Barone M, Allegri M, di Martella Orsi A, Romano M, Sinigaglia B, Auteri G, Vianelli N, Cavo M, Palandri F, Catani L.

Mediators Inflamm. 2018 Jul 4;2018:5974613. doi: 10.1155/2018/5974613. eCollection 2018.

18.

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.

Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.

PMID:
30010187
19.

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting.

De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C.

Blood Cancer J. 2018 Jun 1;8(6):49. doi: 10.1038/s41408-018-0078-3.

20.

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. [Epub ahead of print]

PMID:
29624703
21.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

22.

Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis.

Romano M, Sollazzo D, Trabanelli S, Barone M, Polverelli N, Perricone M, Forte D, Luatti S, Cavo M, Vianelli N, Jandus C, Palandri F, Catani L.

Oncoimmunology. 2017 Jul 5;6(10):e1345402. doi: 10.1080/2162402X.2017.1345402. eCollection 2017.

23.

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M.

Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

24.

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.

Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R.

Am J Hematol. 2018 Jan;93(1):58-64. doi: 10.1002/ajh.24935. Epub 2017 Nov 9.

25.

Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.

Stanzani M, Vianelli N, Cavo M, Maritati A, Morotti M, Lewis RE.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e02651-16. doi: 10.1128/AAC.02651-16. Print 2017 Sep.

26.

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.

Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M.

Hematol Oncol. 2018 Feb;36(1):285-290. doi: 10.1002/hon.2429. Epub 2017 May 17.

PMID:
28512865
27.

Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.

Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabattini E, Villari L, Riminucci M, Valli R, Catani L, Alimena G, Ottaviani E, Fama A, Martinelli G, Perricone M, Spinsanti M, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Feb;36(1):269-275. doi: 10.1002/hon.2430. Epub 2017 May 16.

PMID:
28509339
28.

The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Perricone M, Polverelli N, Martinelli G, Catani L, Ottaviani E, Zuffa E, Franchini E, Dizdari A, Forte D, Sabattini E, Cavo M, Vianelli N, Palandri F.

Oncotarget. 2017 Jun 6;8(23):37239-37249. doi: 10.18632/oncotarget.16744.

29.

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.

Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W, Fattizzo B, Volpetti S, Lucchini E, Polverelli N, Carpenedo M, Isola M, Fanin R, Zaja F.

Eur J Haematol. 2017 Apr;98(4):371-377. doi: 10.1111/ejh.12839. Epub 2017 Jan 20.

PMID:
27981682
30.

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T.

Blood Cancer J. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103.

31.

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F.

Am J Hematol. 2017 Jan;92(1):37-41. doi: 10.1002/ajh.24572. Epub 2016 Nov 12.

32.

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.

Sollazzo D, Forte D, Polverelli N, Perricone M, Romano M, Luatti S, Vianelli N, Cavo M, Palandri F, Catani L.

Mediators Inflamm. 2016;2016:5860657. Epub 2016 Sep 8.

33.

Radiologic findings of Fusarium pneumonia in neutropenic patients.

Sassi C, Stanzani M, Lewis RE, Vianelli N, Tarsi A, Poerio A, Cavo M, Battista G.

Mycoses. 2017 Feb;60(2):73-78. doi: 10.1111/myc.12538. Epub 2016 Jul 29.

PMID:
27470138
34.

Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia.

Boggio E, Gigliotti CL, Rossi D, Toffoletti E, Cappellano G, Clemente N, Puglisi S, Lunghi M, Cerri M, Vianelli N, Cantoni S, Tieghi A, Beggiato E, Gaidano G, Comi C, Chiocchetti A, Fanin R, Dianzani U, Zaja F.

Br J Haematol. 2017 Jan;176(2):258-267. doi: 10.1111/bjh.14248. Epub 2016 Jul 8.

PMID:
27391055
35.

Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.

Sollazzo D, Forte D, Polverelli N, Romano M, Perricone M, Rossi L, Ottaviani E, Luatti S, Martinelli G, Vianelli N, Cavo M, Palandri F, Catani L.

Oncotarget. 2016 Jul 12;7(28):43974-43988. doi: 10.18632/oncotarget.9949.

36.

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.

De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T.

Leukemia. 2016 Oct;30(10):2032-2038. doi: 10.1038/leu.2016.85. Epub 2016 Apr 26.

PMID:
27113812
37.

Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Gugliotta L, Iurlo A, Gugliotta G, Tieghi A, Specchia G, Gaidano G, Scalzulli PR, Rumi E, Dragani A, Martinelli V, Santoro C, Randi ML, Tagariello G, Candoni A, Cattaneo D, Ricco A, Palmieri R, Liberati MA, Langella M, Rago A, Bergamaschi M, Monari P, Miglio R, Santoro U, Cacciola R, Rupoli S, Mastrullo L, Musto P, Mazzucconi MG, Vignetti M, Cortelezzi A, Vianelli N, Martino B, De Stefano V, Passamonti F, Vannucchi AM; Registro Italiano Trombocitemie RIT.

Leuk Res. 2016 Jul;46:18-25. doi: 10.1016/j.leukres.2016.04.004. Epub 2016 Apr 7.

PMID:
27107744
38.

Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.

Palandri F, Polverelli N, Sollazzo D, Romano M, Catani L, Cavo M, Vianelli N.

Am J Hematol. 2016 Jun;91(4):E267-72. doi: 10.1002/ajh.24310.

39.

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.

Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A, Spirito F, Porrini R, De Muro M, Crescenzi Leonetti S, Villivà N, De Gregoris C, Montefusco E, Polverelli N, Santoro C, Breccia M, Cimino G, Majolino I, Mazzucconi MG, Vianelli N, Alimena G, Montanaro M, Palandri F.

Am J Hematol. 2016 Mar;91(3):318-21. doi: 10.1002/ajh.24269.

40.

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.

Palandri F, Polverelli N, Breccia M, Nicolino B, Vitolo U, Alimena G, Cavo M, Vianelli N, Benevolo G.

Br J Haematol. 2016 Jul;174(1):160-2. doi: 10.1111/bjh.13758. Epub 2015 Oct 28. No abstract available.

PMID:
26507357
41.

Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms.

Polverelli N, Catani L, Vianelli N, Baccarani M, Cavo M, Palandri F.

Ann Hematol. 2015 Sep;94(9):1585-7. doi: 10.1007/s00277-015-2397-9. Epub 2015 May 16. No abstract available.

PMID:
25975976
42.

Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia.

Sollazzo D, Polverelli N, Palandri F, Vianelli N, Catani L.

Immunol Lett. 2015 Jul;166(1):63-4. doi: 10.1016/j.imlet.2015.04.006. Epub 2015 May 2. No abstract available.

PMID:
25944583
43.

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.

Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli N.

Leukemia. 2015 Jun;29(6):1344-9. doi: 10.1038/leu.2015.87. Epub 2015 Mar 24.

PMID:
25801912
44.

MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature.

Palandri F, Zoli M, Polverelli N, Noris P, Sollazzo D, Catani L, Vianelli N, Palandri G.

Br J Haematol. 2015 Sep;170(5):729-31. doi: 10.1111/bjh.13324. Epub 2015 Mar 8. Review. No abstract available. Erratum in: Br J Haematol. 2016 Jan;172(1):147.

PMID:
25752999
45.

High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies.

Stanzani M, Sassi C, Lewis RE, Tolomelli G, Bazzocchi A, Cavo M, Vianelli N, Battista G.

Clin Infect Dis. 2015 Jun 1;60(11):1603-10. doi: 10.1093/cid/civ154. Epub 2015 Feb 25.

PMID:
25722200
46.

Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).

Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, Caramatti C, Castagnola C, Cattaneo C, Fanci R, Chierichini A, Melillo L, Mitra ME, Picardi M, Potenza L, Salutari P, Vianelli N, Facchini L, Cesarini M, De Paolis MR, Di Blasi R, Farina F, Venditti A, Ferrari A, Garzia M, Gasbarrino C, Invernizzi R, Lessi F, Manna A, Martino B, Nadali G, Offidani M, Paris L, Pavone V, Rossi G, Spadea A, Specchia G, Trecarichi EM, Vacca A, Cesaro S, Perriello V, Aversa F, Tumbarello M, Pagano L; SEIFEM Group (Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne).

Haematologica. 2015 Feb;100(2):284-92. doi: 10.3324/haematol.2014.113399.

47.

Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry.

Pagano L, Stamouli M, Tumbarello M, Verga L, Candoni A, Cattaneo C, Nadali G, Mitra ME, Mancini V, Nosari A, Garzia MG, Delia M, Storti S, Spadea A, Caramatti C, Perriello V, Sanna M, Vacca A, De Paolis MR, Potenza L, Salutari P, Castagnola C, Fanci R, Chierichini A, Melillo L, Picardi M, Facchini L, Martino B, Di Blasi R, Cesarini M, Offidani M, Vianelli N, Caira M, Lessi F, Ferrari A, Venditti A, Pavone V, Lo-Coco F, Aversa F, Busca A; Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne Group.

Br J Haematol. 2015 Aug;170(3):434-9. doi: 10.1111/bjh.13308. Epub 2015 Jan 27. No abstract available.

PMID:
25626374
48.

Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey.

Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, Nosari A, Caira M, Spadea A, Busca A, Vianelli N, Tumbarello M; HeMABIS Registry—SEIFEM Group, Italy.

Clin Microbiol Infect. 2015 Apr;21(4):337-43. doi: 10.1016/j.cmi.2014.11.022. Epub 2014 Dec 3.

49.

Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.

Palandri F, Polverelli N, Catani L, Vianelli N.

Ann Hematol. 2015 Mar;94(3):519-20. doi: 10.1007/s00277-014-2183-0. Epub 2014 Aug 30. No abstract available.

PMID:
25172457
50.

The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study.

Palandri F, Polverelli N, Catani L, Sollazzo D, Romano M, Levorato M, Vianelli N.

Am J Hematol. 2014 Nov;89(11):1047-50. doi: 10.1002/ajh.23823. Epub 2014 Aug 27.

Supplemental Content

Loading ...
Support Center